Insulin-like growth factor receptor inhibitors: Baby or the bathwater?

Journal of the National Cancer Institute

Volumn 104, Issue 13, 2012, Pages 975-981

  Yee, Douglas ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

A 928605; ABDP; AVE 1642; AXL1717; BI836845; BIIB022; BMS 754807; CARBOPLATIN; CIXUTUMUMAB; DALOTUZUMAB; DOXORUBICIN; ERLOTINIB; EXEMESTANE; FIGITUMUMAB; GANITUMAB; GEMCITABINE; GSK 1904529A; H10H5; INSULIN LIKE GROWTH FACTOR RECEPTOR INHIBITOR; KW 2450; LINSITINIB; MEDI 573; METFORMIN; NORDIHYDROGUAIARETIC ACID; PACLITAXEL; PROTEIN INHIBITOR; R 1507; ROBATUMUMAB; UNCLASSIFIED DRUG; UNINDEXED DRUG; XL 228;

ACROMEGALY; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; DRUG EFFICACY; DRUG MECHANISM; FEEDBACK SYSTEM; GENE EXPRESSION; GENE MUTATION; HUMAN; HYPERGLYCEMIA; HYPOPHYSECTOMY; INSULIN RESISTANCE; LUNG NON SMALL CELL CANCER; NEOPLASM; NONHUMAN; OVARIECTOMY; PANCREAS CANCER; PRIORITY JOURNAL; REVIEW;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BODY HEIGHT; BREAST NEOPLASMS; CARCINOMA, SQUAMOUS CELL; CLINICAL TRIALS AS TOPIC; DISEASE PROGRESSION; EARLY TERMINATION OF CLINICAL TRIALS; ENDOCRINE DISRUPTORS; EVIDENCE-BASED MEDICINE; FEMALE; HUMAN GROWTH HORMONE; HUMANS; HYPERINSULINISM; HYPOPHYSECTOMY; INSULIN-LIKE GROWTH FACTOR I; LUNG NEOPLASMS; NEOPLASMS; OVARIECTOMY; RECEPTOR, IGF TYPE 1; RISK FACTORS; SIGNAL TRANSDUCTION; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 84863900275     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djs258     Document Type: Review

References (55)

1. Karp DD, Paz-Ares LG, Novello S, et al. Phase II study of the antiinsulin-like growth factor type 1 receptor antibody CP-751,871 in combination with paclitaxel and carboplatin in previously untreated, locally advanced, or metastatic non-small-cell lung cancer. J Clin Oncol. 2009;27(15):2516-2522.
2. Kaufman PA, Ferrero JM, Bourgeois H, et al. A randomized, double-blind, placebo-controlled, phase 2 study of AMG 479 with exemestane (E) or fulvestrant (F) in postmenopausal women with hormone-receptor positive (HR+) metastatic (M) or locally advanced (LA) breast cancer (BC). Cancer Res. 2010;70(suppl 24):76s.
3. Ramalingam SS, Spigel DR, Chen D, et al. Randomized phase II study of erlotinib in combination with placebo or R1507, a monoclonal antibody to insulin-like growth factor-1 receptor, for advanced-stage non-small-cell lung cancer. J Clin Oncol. 2011;29(34):4574-4580.
4. Ahlgren M, Melbye M, Wohlfahrt J, Sorensen TI. Growth patterns and the risk of breast cancer in women. N Engl J Med. 2004;351(16):1619-1626.
5. Green J, Cairns BJ, Casabonne D, Wright FL, Reeves G, Beral V. Height and cancer incidence in the Million Women Study: prospective cohort, and meta-analysis of prospective studies of height and total cancer risk. Lancet Oncol. 2011;12(8):785-794.
6. Hankinson SE, Willett WC, Colditz GA, et al. Circulating concentrations of insulin-like growth factor-I and risk of breast cancer. Lancet. 1998;351:1373-1375.
7. Chan JM, Stampfer MJ, Giovannucci E, et al. Plasma insulin-like growth factor-I and prostate cancer risk: a prospective study. Science. 1998;279(5350):563-565.
8. Shevah O, Laron Z. Patients with congenital deficiency of IGF-I seem protected from the development of malignancies: a preliminary report. Growth Horm IGF Res. 2007;17(1):54-57.
9. Guevara-Aguirre J, Balasubramanian P, Guevara-Aguirre M, et al. Growth hormone receptor deficiency is associated with a major reduction in pro-aging signaling, cancer, and diabetes in humans. Sci Transl Med. 2011;3(70):70ra13.
10. Ray BS, Pearson OH. Hypophysectomy in treatment of disseminated breast cancer. Surg Clin North Am. 1962;42:419-433.
11. Pearson OH, West CD, Li MC, Maclean JP, Treves N. Endocrine therapy of metastatic breast cancer. AMA Arch Intern Med. 1955;95(2):357-364.
12. Arteaga CL, Kitten LJ, Coronado EB, et al. Blockade of the type I somatomedin receptor inhibits growth of human breast cancer cells in athymic mice. J Clin Invest. 1989;84:1418-1423.
13. Garcia-Echeverria C, Pearson MA, Marti A, et al. In vivo antitumor activity of NVP-AEW541: a novel, potent, and selective inhibitor of the IGF-IR kinase. Cancer Cell. 2004;5(3):231-239.
14. Sachdev D, Yee D. Disrupting insulin-like growth factor signaling as a potential cancer therapy. Mol Cancer Ther. 2007;6(1):1-12.
15. Belfiore A, Roberta M. The insulin receptor and cancer. Endocr Relat Cancer. 2011;18(4):R125-R147.
16. Kaleko M, Rutter WJ, Miller AD. Overexpression of the human insulinlike growth factor I receptor promotes ligand-dependent neoplastic transformation. Mol Cell Biol. 1990;10(2):464-473.
17. Frasca F, Pandini G, Scalia P, et al. Insulin receptor isoform A, a newly recognized, high-affinity insulin-like growth factor II receptor in fetal and cancer cells. Mol Cell Biol. 1999;19(5):3278-3288.
18. Tobin G, Yee D, Brunner N, Rotwein P. A novel human insulin-like growth factor I messenger RNA is expressed in normal and tumor cells. Mol Endocrinol. 1990;4(12):1914-1920.
19. Jogie-Brahim S, Feldman D, Oh Y. Unraveling insulin-like growth factor binding protein-3 actions in human disease. Endocr Rev. 2009;30(5):417-437.
20. Sachdev D, Li SL, Hartell JS, Fujita-Yamaguchi Y, Miller JS, Yee D. A chimeric humanized single-chain antibody against the type I insulin-like growth factor (IGF) receptor renders breast cancer cells refractory to the mitogenic effects of IGF-I. Cancer Res. 2003;63(3):627-635.
21. Kwak EL, Bang YJ, Camidge DR, et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med. 2010;363(18):1693-1703.
22. Zhang H, Pelzer AM, Kiang DT, Yee D. Down-regulation of type I insulinlike growth factor receptor increases sensitivity of breast cancer cells to insulin. Cancer Res. 2007;67(1):391-397.
23. Avnet S, Sciacca L, Salerno M, et al. Insulin receptor isoform A and insulinlike growth factor II as additional treatment targets in human osteosarcoma. Cancer Res. 2009;69(6):2443-2452.
24. Hou X, Harrington SC, Macedo LF, Weroha SJ, Brodie A, Haluska P. Hormonal therapies differentially enhance insulin receptor isoform A and erbB receptor up-regulation in response to IGF-1R inhibitor MK-0646 in vivo [abstract]. Proc Am Assoc Cancer Res. 2009;Abs 2812.
25. Gualberto A, Dolled-Filhart M, Gustavson M, et al. Molecular analysis of non-small cell lung cancer identifies subsets with different sensitivity to insulin-like growth factor I receptor inhibition. Clin Cancer Res. 2010;16(18):4654-4665.
26. Spears M, Taylor KJ, Munro AF, et al. In situ detection of HER2:HER2 and HER2:HER3 protein-protein interactions demonstrates prognostic significance in early breast cancer. Breast Cancer Res Treat. 2012;132(2):463-470.
27. Litzenburger BC, Creighton CJ, Tsimelzon A, et al. High IGF-IR activity in triple-negative breast cancer cell lines and tumorgrafts correlates with sensitivity to anti-IGF-IR therapy. Clin Cancer Res. 2011;17(8):2314-2327.
28. Haluska P, Shaw HM, Batzel GN, et al. Phase I dose escalation study of the anti insulin-like growth factor-I receptor monoclonal antibody CP-751,871 in patients with refractory solid tumors. Clin Cancer Res. 2007;13(19):5834-5840.
29. Tolcher AW, Sarantopoulos J, Patnaik A, et al. Phase I, pharmacokinetic, and pharmacodynamic study of AMG 479, a fully human monoclonal antibody to insulin-like growth factor receptor 1. J Clin Oncol. 2009;27(34):5800-5807.
30. Atzori F, Tabernero J, Cervantes A, et al. A phase I pharmacokinetic and pharmacodynamic study of dalotuzumab (MK-0646), an anti-insulin-like growth factor-1 receptor monoclonal antibody, in patients with advanced solid tumors. Clin Cancer Res. 2011;17(19):6304-6312.
31. van Garderen E, Schalken JA. Morphogenic and tumorigenic potentials of the mammary growth hormone/growth hormone receptor system. Mol Cell Endocrinol. 2002;197(1-2):153-165.
32. Moller N, Jorgensen JO. Effects of growth hormone on glucose, lipid, and protein metabolism in human subjects. Endocr Rev. 2009;30(2):152-177.
33. DeChiara TM, Efstratiadis A, Robertson EJ. A growth-deficiency phenotype in heterozygous mice carrying an insulin-like growth factor II gene disrupted by targeting. Nature. 1990;345(6270):78-80.
34. Sachdev D, Hartell JS, Lee AV, Zhang X, Yee D. A dominant negative type I insulin-like growth factor receptor inhibits metastasis of human cancer cells. J Biol Chem. 2004;279(6):5017-5024.
35. Nagle JA, Ma Z, Byrne MA, White MF, Shaw LM. Involvement of insulin receptor substrate 2 in mammary tumor metastasis. Mol Cell Biol. 2004;24(22):9726-9735.
36. Byron SA, Horwitz KB, Richer JK, Lange CA, Zhang X, Yee D. Insulin receptor substrates mediate distinct biological responses to insulinlike growth factor receptor activation in breast cancer cells. Br J Cancer. 2006;95(9):1220-1228.
37. Cho HS, Aronica SM, Katzenellenbogen BS. Regulation of progesterone receptor gene expression in MCF-7 breast cancer cells-a comparison of the effects of cyclic adenosine 3′,5′-monophosphate, estradiol, insulin-like growth factor-I, and serum factors. Endocrinology. 1994;134(2):658-664.
38. Becker MA, Ibrahim YH, Cui X, Lee AV, Yee D. The IGF pathway regulates ERalpha through a S6K1-dependent mechanism in breast cancer cells. Mol Endocrinol. 2011;25(3):516-528.
39. Drury SC, Detre S, Leary A, et al. Changes in breast cancer biomarkers in the IGF1R/PI3K pathway in recurrent breast cancer after tamoxifen treatment. Endocr Relat Cancer. 2011;18(5):565-577.
40. Morgillo F, Kim WY, Kim ES, Ciardiello F, Hong WK, Lee HY. Implication of the insulin-like growth factor-IR pathway in the resistance of non-small cell lung cancer cells to treatment with gefitinib. Clin Cancer Res. 2007;13(9):2795-2803.
41. Zeng X, Zhang H, Oh A, Zhang Y, Yee D. Enhancement of doxorubicin cytotoxicity of human cancer cells by tyrosine kinase inhibition of insulin receptor and type I IGF receptor. Breast Cancer Res Treat. 2012;133(1):117-126.
42. Khatri A, Brundage RC, Hull JM, Williams BW, Yee D, Kirstein MN. Pharmacodynamic modeling of sequence-dependent antitumor activity of insulin-like growth factor blockade and gemcitabine. AAPS J. 2012;14(1):1-9.
43. Olmos D, Postel-Vinay S, Molife LR, et al. Safety, pharmacokinetics, and preliminary activity of the anti-IGF-1R antibody figitumumab (CP-751,871) in patients with sarcoma and Ewing's sarcoma: a phase 1 expansion cohort study. Lancet Oncol. 2010;11(2):129-135.
44. Haluska P, Worden F, Olmos D, et al. Safety, tolerability, and pharmacokinetics of the anti-IGF-1R monoclonal antibody figitumumab in patients with refractory adrenocortical carcinoma. Cancer Chemother Pharmacol. 2010;65(4):765-773.
45. Pappo AS, Patel SR, Crowley J, et al. R1507, a monoclonal antibody to the insulin-like growth factor 1 receptor in patients with recurrent or refractory Ewing sarcoma family of tumors: results of a phase II Sarcoma Alliance for Research through Collaboration Study. J Clin Oncol. 2011;29(34):4541-4547.
46. Lu J, Deng H, Tang RP, et al. Exposure-response (E-R) analysis to facilitate phase III (P3) dose selection for ganitumab (GAN, AMG 479) in combination with gemcitabine (G) to treat metastatic pancreatic cancer (mPC). J Clin Oncol. 2011;29:abstr 4049.
47. Ryan PD, Neven P, Blackwell KL, et al. Figitumumab plus exemestane versus exemestane as first-line treatment of postmenopausal hormone receptor-positive advanced breast cancer: a randomized, open-label phase II trial. Cancer Res. 2011;71(suppl 24):239s, Abs nr P1-17-01.
48. Barker AD, Sigman CC, Kelloff GJ, Hylton NM, Berry DA, Esserman LJ. I-SPY 2: an adaptive breast cancer trial design in the setting of neoadjuvant chemotherapy. Clin Pharmacol Ther. 2009;86(1):97-100.
49. Dowling RJ, Goodwin PJ, Stambolic V. Understanding the benefit of metformin use in cancer treatment. BMC Med. 2011;9:33.
50. Fierz Y, Novosyadlyy R, Vijayakumar A, Yakar S, LeRoith D. Mammalian target of rapamycin inhibition abrogates insulin-mediated mammary tumor progression in type 2 diabetes. Endocr Relat Cancer. 2010;17(4):941-951.
51. Di Cosimo S, Bendell JC, Cervantes-Ruiperez A, et al. A phase I study of the oral mTOR inhibitor ridaforolimus (RIDA) in combination with the IGF-1R antibody dalotozumab (DALO) in patients (pts) with advanced solid tumors. J Clin Oncol. 2010;28(15):abstr 3008.
52. O'Reilly KE, Rojo F, She QB, et al. mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res. 2006;66(3):1500-1508.
53. Naing A, Lorusso P, Fu S, et al. Insulin growth factor-receptor (IGF-1R) antibody cixutumumab combined with the mTOR inhibitor temsirolimus in patients with refractory Ewing's sarcoma family tumors. Clin Cancer Res. 2012;18(9):2625-2631.
54. Novosyadlyy R, Lann DE, Vijayakumar A, et al. Insulin-mediated acceleration of breast cancer development and progression in a nonobese model of type 2 diabetes. Cancer Res. 2010;70(2):741-751.
55. Dool C, Mashhedi H, Zakikhani M, et al. IGF-1/insulin receptor kinase inhibition by BMS-536924 is better tolerated than alloxan-induced hypoinsulinemia and more effective than metformin in the treatment of experimental insulin responsive breast cancer. Endocr Relat Cancer. 2011;18(6):699-709.